GSK, Pharmacopeia Pact Yields New Leads
Posted on November 27, 2007 @ 07:26 am
Pharmacopeia has identified a pair of new lead compounds for advancement in its alliance with GlaxoSmithKline. The first of the lead compounds forms the basis of a new lead optimization program focused on identifying a treatment for respiratory disease. The other newly identified lead compound is the second from a program in inflammatory pain. As a result of the identification of these new lead compounds, Pharmacopeia will receive milestone payments totaling $1 million from GSK, which is conducting the work through its Center of Excellence for External Drug Discovery (CEEDD)
Pharmacopeia has received $10 million from GSK in connection with early discovery activities and is entitled to an additional $5 million payment upon the completion. Pharmacopeia is also entitled to success-based milestone payments totaling as much as $83 million per program and potential double-digit royalties on the sales of any product commercialized by GSK under the multi-program alliance. Should GSK decline its option to complete pivotal trials of alliance programs, Pharmacopeia may independently pursue them, subject to its obligations to GSK under the agreement.
先导物能卖好价钱，以前看到很多国内高校、研究单位有些多类似先导物之类的东西，在国内寻找卖家，但厂家往往不感兴趣。
Posted on November 27, 2007 @ 07:26 am
Pharmacopeia has identified a pair of new lead compounds for advancement in its alliance with GlaxoSmithKline. The first of the lead compounds forms the basis of a new lead optimization program focused on identifying a treatment for respiratory disease. The other newly identified lead compound is the second from a program in inflammatory pain. As a result of the identification of these new lead compounds, Pharmacopeia will receive milestone payments totaling $1 million from GSK, which is conducting the work through its Center of Excellence for External Drug Discovery (CEEDD)
Pharmacopeia has received $10 million from GSK in connection with early discovery activities and is entitled to an additional $5 million payment upon the completion. Pharmacopeia is also entitled to success-based milestone payments totaling as much as $83 million per program and potential double-digit royalties on the sales of any product commercialized by GSK under the multi-program alliance. Should GSK decline its option to complete pivotal trials of alliance programs, Pharmacopeia may independently pursue them, subject to its obligations to GSK under the agreement.
先导物能卖好价钱，以前看到很多国内高校、研究单位有些多类似先导物之类的东西，在国内寻找卖家，但厂家往往不感兴趣。